Our latest news
Court approval received for the cancellation of share premium account
22 December 2008
Source BioScience confirms that it has now received Court approval for the cancellation of the share premium account.
Source BioScience provides Interim Management Statement
19 November 2008
Source BioScience today provides its Interim Management Statement as required by the UK Listing Authority's Disclosure and Transparency Rules, relating to the period from 1 July 2008 to 19 November 2008.
Source BioScience opens new DNA sequencing facility based at University College London
17 November 2008
The Company is pleased to announce the opening of its new DNA sequencing and genotyping facility based at University College London ('UCL').
Source BioScience expands distributor network in East Asia
04 November 2008
The Company is pleased to announce an expansion of its distributor network for its Geneservice and Autogen Bioclear life science research products and services in the East Asian market.
Source BioScience to offer the Roche AmpliChip CYP450 diagnostic test
06 October 2008
Source BioScience is pleased to announce the addition of the Roche AmpliChip CYP450 test to its portfolio of diagnostic testing services.
National Cancer Research Institute (NCRI) Cancer Conference, 5-8 October, The International Convention Centre, Birmingham
24 September 2008
Source BioScience will have a stand at the NCRI Conference in Birmingham next month, providing an ideal opportunity to network with a wide range of cancer specialists in both healthcare and academia.There are 200 different types of cancer with 289,000 new cases diagnosed each year in the UK � 1 in 3 people will develop some form of cancer in their lifetime � so being able to respond efficiently and effectively to cancer treatment is a key priority in healthcare. As a highly focused healthcare and biotechnology company offering expert, quality services and products to the healthcare, pharma biotech and life science research sectors, Source BioScience is at the forefront of many of the technologies which can offer precise diagnosis to help target the most effective treatment for a range of cancers. They also supply products and undertake work with academic institutions to help develop further our understanding of the role of DNA in the disease process. The Commercial team, located on Stand 32, will be on hand to meet with anyone wishing to discuss how Source BioScience can help in the fields of diagnostic and molecular pathology. Should you wish to pre-book some time with a member of the team, please contact Roger Coombes, Head of Healthcare � firstname.lastname@example.org.